Literature DB >> 7690091

Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients.

E Grossman1, T Rosenthal, E Peleg, C Holmes, D S Goldstein.   

Abstract

Yohimbine is an alpha 2-adrenoceptor antagonist that is FDA approved for treatment of impotence. The drug is an indolalkylamine alkaloid chemically similar to reserpine and is believed to act through sympatholysis. We examined effects of oral yohimbine on blood pressure (BP) and plasma levels of catechols in patients with essential hypertension, a condition in which most drug treatments can produce impotence. In 25 unmedicated hypertensive subjects, vital signs were measured and blood samples were obtained through an indwelling antecubital venous catheter at baseline and 1 and 2 h after subjects ingested 4 5.4-mg tablets of yohimbine. Mean blood pressure (MBP) increased by an average of 5 mm Hg (p < 0.01), plasma norepinephrine (NE) levels increased by 66% (p < 0.001), and plasma dihydroxyphenylglycol (DHPG) levels increased by 25% (p < 0.01) at 1 h after drug administration. The magnitude of the pressor response was unrelated to baseline MBP but positively correlated with the baseline NE level (r = 0.61, p < 0.01) and with the yohimbine-induced increment in plasma NE (r = 0.4, p < 0.01). The results indicate that yohimbine does not inhibit and actually stimulates sympathetically mediated NE release in humans and that the increased NE release produces a pressor response. Yohimbine should be administered with caution to patients with high BP, especially in individuals with evidence for increased basal sympathetic outflow or those undergoing concurrent treatment with tricyclic antidepressants or other drugs that interfere with neuronal uptake or metabolism of NE.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690091     DOI: 10.1097/00005344-199307000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  14 in total

1.  [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

Authors:  A P Davenport; R E Kuc; S L Hoskins; F E Karet; F Fitzgerald
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

2.  Hypertensive urgency: an important aetiology of rebound hypertension.

Authors:  John Malaty; Irene A Malaty
Journal:  BMJ Case Rep       Date:  2014-10-21

3.  ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

Review 4.  Herbs and alternative therapies: relevance to hypertension and cardiovascular diseases.

Authors:  Chaula K Vora; George A Mansoor
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

5.  Endothelin receptors in human coronary artery and aorta.

Authors:  C R Bacon; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 6.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

7.  Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro.

Authors:  J J Maguire; R E Kuc; G O'Reilly; A P Davenport
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

Review 8.  Neurogenic orthostatic hypotension: a pathophysiological approach.

Authors:  David S Goldstein; Yehonatan Sharabi
Journal:  Circulation       Date:  2009-01-06       Impact factor: 29.690

9.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.

Authors:  A P Davenport; G O'Reilly; R E Kuc
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.